Insider trade

Detailed view of a single trade
Back to trades
Ticker
TRMED
Thor Medical ASA
Trade ID
17773
Message 634406
Trade snapshot
BUY RIGHTS_ISSUE
Trade date
2024-12-12
Published
2024-12-11 23:55
Insider
Sindre Hassfjell
CTO
Relation
DIRECT
Sindre Hassfjell
Shares
80 000.00
Price
n/a
Total
n/a
Holdings after
n/a
Instrument
SHARE
Include in scoring
No
Returns
Horizon Target date Price date Close Return
Base 2024-12-12 2024-12-12 2.78 n/a
1m 2025-01-12 2025-01-13 2.40 -13.5%
3m 2025-03-12 2025-03-12 2.10 -24.3%
12m 2025-12-12 2025-12-12 4.11 48.1%
Message
Thor Medical ASA: Allocation of shares to primary insiders and their close associates in the Private Placement
12.12.2024 00:55:06 CET | Thor Medical ASA | Mandatory notification of trade
primary insiders

Oslo, Norway, 12 December 2024: Reference is made to the stock exchange
announcement by Thor Medical ASA (the "Company") on 11 December 2024 regarding a
private placement of new shares to be issued by the Company (the "Private
Placement").

The following primary insiders and close associates have been allocated shares
in the Private Placement, as further specified in the attached notification
forms:

* Scatec Innovation AS, a close associate of board member John Andersen, has
been allocated 12,000,000 shares ;
* Jasper Kurth, the CEO, has been allocated 400,000 shares;
* Sindre Hassfjell the CTO, has been allocated 80,000 shares;
* Alf Bjørseth, SVP Business Development, has been allocated 400,000 shares;
* Ludvik Sandnes, the chair of the board, has been allocated 140,000 shares;
and
* B Good Industries AS, a close associated of primary insider Brede Ellingsæter
the CFO, has been allocated 400,000 shares;



This information is subject to disclosure requirements pursuant to the EU Market
Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section
5-12.



Contacts

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com



ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no -
https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18356877/5408/Download%20announce
ment%20as%20PDF.pdf

20241211 - Primary insider notifications.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18356877/5407/20241211%20-%20Prim
ary%20insider%20notifications.pdf
Message ID 634406
Primary insider
Sindre petter Hassfjell
CTO
TRMED · Thor Medical ASA